A viral E3 ubiquitin ligase produced by herpes simplex virus 1 inhibits the NLRP1 inflammasome
Journal of Experimental Medicine · 2024
DOI: 10.1084/jem.20231518 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Experimental Medicine, 2024. Verfasst von Pooja Parameswaran und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Infectious Diseases and Immunology, University of Massachusetts Chan Medical School, Worcester, MA, USA. Hauptthemen laut MEDLINE: Inflammasomes, Ubiquitin-Protein Ligases, Herpesvirus 1, Human, NLR Proteins. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0). Gefördert von: NIAID NIH HHS, UMass Chan Medical School, Richard and Susan Smith Family Foundation.
Abstract (Originalsprache)
Guard proteins initiate defense mechanisms upon sensing pathogen-encoded virulence factors. Successful viral pathogens likely inhibit guard protein activity, but these interactions have been largely undefined. Here, we demonstrate that the human pathogen herpes simplex virus 1 (HSV-1) stimulates and inhibits an antiviral pathway initiated by NLRP1, a guard protein that induces inflammasome formation and pyroptotic cell death when activated. Notably, HSV-1 infection of human keratinocytes promotes posttranslational modifications to NLRP1, consistent with MAPK-dependent NLRP1 activation, but does not result in downstream inflammasome formation. We identify infected cell protein 0 (ICP0) as the critical HSV-1 protein that is necessary and sufficient for inhibition of the NLRP1 pathway. Mechanistically, ICP0’s cytoplasmic localization and function as an E3 ubiquitin ligase prevents proteasomal degradation of the auto-inhibitory NT-NLRP1 fragment, thereby preventing inflammasome formation. Further, we demonstrate that inhibiting this inflammasome is important for promoting HSV-1 replication. Thus, we have established a mechanism by which HSV-1 overcomes a guard-mediated antiviral defense strategy in humans.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Division of Infectious Diseases and Immunology, University of Massachusetts Chan Medical School, Worcester, MA, USA.
- Program in Innate Immunity, University of Massachusetts Chan Medical School , Worcester, MA, USA.
- Immunology and Microbiology Program, Morningside Graduate School of Biomedical Sciences, University of Massachusetts Chan Medical School , Worcester, MA, USA.
- Department of Dermatology, University of Massachusetts Chan Medical School, Worcester, MA, USA.
ORCID-Profile: Pooja Parameswaran, Laurellee Payne, Jennifer Powers, Mehdi Rashighi, Megan H Orzalli
Förderung
- NIAID NIH HHS
- UMass Chan Medical School
- Richard and Susan Smith Family Foundation
- NIH HHS
- National Institutes of Health
Zitieren
APA
Parameswaran, P., Payne, L., Powers, J., Rashighi, M., & Orzalli, M. H. (2024). A viral E3 ubiquitin ligase produced by herpes simplex virus 1 inhibits the NLRP1 inflammasome. Journal of Experimental Medicine. https://doi.org/10.1084/jem.20231518
Vancouver
Parameswaran P, Payne L, Powers J, Rashighi M, Orzalli MH. A viral E3 ubiquitin ligase produced by herpes simplex virus 1 inhibits the NLRP1 inflammasome. Journal of Experimental Medicine. 2024. doi:10.1084/jem.20231518
BibTeX
@article{Parameswaran2024,
author = {Parameswaran, Pooja and Payne, Laurellee and Powers, Jennifer and Rashighi, Mehdi and Orzalli, Megan H},
title = {A viral E3 ubiquitin ligase produced by herpes simplex virus 1 inhibits the NLRP1 inflammasome},
journal = {Journal of Experimental Medicine},
year = {2024},
doi = {10.1084/jem.20231518}
}
EUVIMED